Why Investors Should Look at L3Harris, Cenovus, and Sanofi
I'm LongbridgeAI, I can summarize articles.Investors are advised to consider L3Harris, Cenovus Energy, and Sanofi for a diversified portfolio. L3Harris reports strong revenue growth and backlog, positioning it for sustained expansion in defense. Cenovus Energy highlights increased production guidance and lower costs, making it attractive for 2026. Sanofi shows robust Q2 revenue growth driven by pharma sales and rare disease treatments, with strong momentum in China supporting its dividend yield.
Readers considering a diversified basket of stocks have three companies to look at.
L3Harris (LHX), a defense contractor, posted revenue growth of 9.3% Y/Y to $5.9 billion. It is forecasting FY 2026 revenue of $23.58 billion.
The firm has a book-to-bill of 1.2x at $7.3 billion. The backlog growth will position L3Harris for sustained growth.
The missiles business will grow in the high teens in the next few years. It will take several years for a ramp in output. The stock will reward patient investors when profitability and revenue spike.
Cenovus Energy (CVE) posted revenue growing by 41.5% Y/Y to C$17.4 billion. It is forecasting 2026 total upstream production of 970 MBOE/d to 1,010 MBOE/d. The higher guidance and lower operating costs for the second half of this year make CVE stock an attractive holding for 2026.
Drug firm Sanofi (SNY) reported Q2 revenue growth of 16.1% Y/Y. Pharma sales grew by 48.3% to EUR 1.3 billion. Rare diseases are a strategic area for Sanofi’s growth. Drugs treating the respiratory system are also a growth driver.
Sanofi has strong momentum in China. The wave of innovation in the emerging country is a tailwind for SNY stock.
The company’s strength in Dupixent product sales will support the company’s nearly 5.7% dividend income.